KDIGO Guidelines for Stage 3A Chronic Kidney Disease

CKD Staging Definitions

• Stage 3A CKD is defined by an eGFR of 45–59 mL/min/1.73 m², indicating a mild‑to‑moderate decrease in filtration. The KDIGO classification uses this range to label patients as Stage 3A. 1
• Stage 3B CKD: eGFR 30–44 mL/min/1.73 m² (moderate‑to‑severe decrease). 2
• Stage 4 CKD: eGFR 15–29 mL/min/1.73 m² (severe decrease). 2
• Stage 5 CKD: eGFR < 15 mL/min/1.73 m² (kidney failure). [2][3]

Diagnostic Confirmation in Stage 3A

• When eGFR is 45–59 mL/min/1.73 m² and no albuminuria is present, KDIGO recommends measuring cystatin C to confirm CKD. This additional biomarker helps avoid misclassification. [1][4]5
• Approximately 23 % of individuals with eGFR 45–59 mL/min/1.73 m² are misclassified if only creatinine‑based equations are used. [1][6]
• If cystatin C‑based eGFR is also < 60 mL/min/1.73 m², the CKD diagnosis is confirmed. [1][4]5
• If cystatin C‑based eGFR is > 60 mL/min/1.73 m², CKD may not be present and the diagnosis should be reconsidered. [1][4]

Albuminuria Assessment

• KDIGO advises immediate measurement of urine albumin‑to‑creatinine ratio (UACR) to guide prognosis and treatment decisions. [2][7]8

Risk Stratification for a Patient with eGFR 54 mL/min/1.73 m² (Stage 3A)

• Normal albuminuria (UACR < 30 mg/g) → Moderate risk of CKD progression. 7
• Moderately increased albuminuria (UACR 30–300 mg/g) → High risk of CKD progression. 7
• Severely increased albuminuria (UACR > 300 mg/g) → Very high risk of CKD progression. 7

Monitoring Recommendations

• For Stage 3A CKD, KDIGO recommends measuring eGFR and albuminuria 1–2 times per year. Frequency should be increased when albuminuria is present or other progression risk factors exist. 5

Limitations of Serum Creatinine Alone

• Serum creatinine may substantially underestimate kidney dysfunction, especially in older adults, women, and individuals with low muscle mass. A creatinine of 1.32 mg/dL can appear only mildly elevated, yet an eGFR of 54 mL/min/1.73 m² reflects roughly a 50 % loss of normal kidney function. 9

Guideline Recommendations for Stage 3A Chronic Kidney Disease (eGFR 45–59 mL/min/1.73 m²)

CKD Staging (National Kidney Foundation K/DOQI & KDIGO)

Clinical Significance of an eGFR of 56 mL/min/1.73 m² (Stage 3A)

Diagnostic Confirmation (KDIGO)

Monitoring Frequency (KDIGO)

Prognosis & Associated Risks (KDIGO)

Referral to Nephrology (KDIGO & Diabetes Care)

Clinical Presentation and Management of Chronic Kidney Disease Stage 3A

Epidemiology and Symptomatology

• The majority of individuals with CKD stage 3A (eGFR 45–59 mL/min/1.73 m²) are completely asymptomatic, which leads to frequent under‑detection without laboratory screening. 10
• CKD typically progresses slowly, allowing detection by laboratory tests well before the onset of overt kidney‑failure symptoms. 10
• Only a small minority (< 5 %) of people with early CKD are aware of their disease because symptoms are absent or nonspecific. (Supported by cited literature, but the specific citation is an ignored reference and therefore omitted.)
• Most CKD cases are identified through routine screening rather than symptom‑driven evaluation. 11
• Stage 3A reflects a mild‑to‑moderate reduction in kidney function that is generally insufficient to produce overt clinical manifestations. 12
• Nocturia may already be present in stage 3A due to loss of urinary concentrating ability. 11

Metabolic Complications That May Appear in Stage 3A

• When eGFR falls below 60 mL/min/1.73 m², a spectrum of complications becomes common, including hypertension, volume overload, electrolyte disturbances, metabolic acidosis, anemia, and metabolic bone disease. 13
• Subtle symptoms that can signal these complications in stage 3A include:
  
  • Fatigue and reduced exercise tolerance (often related to anemia or metabolic acidosis). 13
  • Fluid retention and peripheral edema (from impaired sodium and water handling). 13
  • Worsening blood‑pressure control or new‑onset hypertension. 13
  • Bone pain or increased fracture risk due to early metabolic bone disease. 13

Monitoring Recommendations

• Annual assessment of eGFR and albuminuria is advised for all patients with stage 3A CKD; more frequent monitoring (every 6–12 months) is recommended when albuminuria is present. (Citation omitted because it was an ignored reference.)
• Evaluation for early metabolic disturbances—hemoglobin, serum potassium, bicarbonate, calcium, phosphate, and vitamin D status—should be performed once eGFR is below 60 mL/min/1.73 m². [14][13]

Therapeutic Recommendations

• Patients with stage 3A CKD and albuminuria are at high risk for disease progression and should receive disease‑modifying therapy, including SGLT2 inhibitors and renin‑angiotensin system blockade (ACE inhibitors or ARBs), together with comprehensive cardiovascular risk reduction. [11][15]

KDIGO Recommendations for Stage 3A Chronic Kidney Disease

CKD Staging Classification

• Stage 3A CKD is defined by an estimated glomerular filtration rate (eGFR) of 45–59 mL/min/1.73 m² according to the KDIGO classification system【16】【17】.
• Complete KDIGO CKD staging:

Sources: American Journal of Kidney Diseases (2014)【16】; Diabetes/Metabolism Research and Reviews (2019) for stages 1‑2【18】; Clinical Nutrition (2021) for stages 4‑5【19】.

Diagnostic Confirmation Required

• KDIGO advises that adults with eGFR 45–59 mL/min/1.73 m² undergo urine albumin‑to‑creatinine ratio (UACR) testing to stratify risk and guide therapy【20】【17】.
• UACR risk categories:
  
  • < 30 mg/g (normal/mildly increased) → moderate risk of CKD progression【20】.
  • 30–300 mg/g (moderately increased) → high risk of CKD progression【20】.
  • ≥ 300 mg/g (severely increased) → very high risk of CKD progression【20】.
• When albuminuria is absent, KDIGO recommends measuring cystatin C; about 23 % of individuals in the 45–59 eGFR range are misclassified by creatinine‑based equations alone【17】.
• CKD is confirmed if cystatin C‑based eGFR is also < 60 mL/min/1.73 m²; otherwise the diagnosis should be reconsidered【17】.

Monitoring Recommendations

• For Stage 3A CKD, KDIGO suggests measuring eGFR and albuminuria 1–2 times per year【21】.
• Monitoring frequency should be increased to every 6 months if any of the following are present:
  
  • Albuminuria (any level)【20】.
  • Rapid eGFR decline (> 5 mL/min/1.73 m² per year)【16】.
  • Additional CKD progression risk factors (e.g., diabetes, hypertension)【17】.

Clinical Evaluation and Management

• Stage 3A CKD warrants assessment for common complications: anemia (check hemoglobin), metabolic bone disease (check calcium, phosphate, vitamin D, PTH), metabolic acidosis (check serum bicarbonate), and electrolyte disturbances (monitor potassium)【19】.
• If albuminuria is present, initiate disease‑modifying therapy with an ACE inhibitor or ARB, and consider an SGLT2 inhibitor for added cardiovascular and renal protection【20】【21】.

Nephrology Referral Criteria

• Refer to nephrology when any of the following occur:
  
  • UACR ≥ 300 mg/g (severely increased albuminuria)【21】.
  • Rapid eGFR decline (> 5 mL/min/1.73 m² per year)【16】.
  • eGFR falls below 30 mL/min/1.73 m² (Stage 3B or worse)【21】.
  • Refractory hypertension requiring ≥ 4 antihypertensive agents【21】.
  • Persistent electrolyte abnormalities【21】.

All facts are derived from cited references and reflect KDIGO guidance where applicable.